Leishmania tropica in northern Israel: A clinical overview of an emerging focus

Shani-Adir, Ayelet; Kamil, Stephanie; Rozenman, Dganit; Schwartz, Eli; Ramon, Michal; Zalman, Lucia; Nasereddin, Abedelmajeed; Jaffe, Charles L.; Ephros, Moshe

doi:10.1016/j.jaad.2005.07.026

Cited by 40 publications

(34 citation statements)

References 23 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48 In a recent published article from Israel, the complete response to treatment was observed in 6 of 9 patients (67%) treated with intralesional injections of SSG and in 4 of 5 patients (80%) treated with intravenous SSG. 85 The wide range of reported cure rates may be partly explained by different definition for primary outcome and causative protozoa. Emerging resistance to pentavalent antimonies was observed in some endemic areas in Iran where CL is caused by L tropica, 86 which might contribute to low responsiveness of CL cases to treatment with MA.…”

Section: Pentavalent Antimoniesmentioning

confidence: 99%

Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials

Khatami

Firooz

Gorouhi

et al. 2007

Journal of the American Academy of Dermatology

117

View full text Add to dashboard Cite

Section: Pentavalent Antimoniesmentioning

confidence: 99%

Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials

Khatami

Firooz

Gorouhi

et al. 2007

Journal of the American Academy of Dermatology

117

View full text Add to dashboard Cite

“…Topikal paromomycin L. major lezyonlarında kullanılabilir (48). Paromomycin %15 ve methylbenzethonium %12 içeren merhem (Leishcutan®) L. majorlü 67 olgunun %87'sinde etkili bulunmuştur.…”

Section: Resim 4 Yaymada Makrofajlar Içinde Ve Dışında Amastigotlar unclassified

Cutaneous Leishmaniasis

Harman¹

2015

tdd

View full text Add to dashboard Cite

Leishmaniasis, leishmania türlerinin neden olduğu ve enfekte dişi tatarcıkların ısırmasıyla insanlara bulaşan bir dizi hastalığı tanımlamaktadır. Hastalığın kutanöz, mukokutanöz ve visseral olmak üzere üç ana formu bulunmaktadır. Dünya Sağlık Örgütü verilerine göre, tüm dünyada toplam 98 ülkede yaklaşık 12 milyon insan leishmaniasise yakalanmış durumda olup, 350 milyon kişinin ise risk altında yaşadığı bildirilmektedir. Her yıl bu rakamlara 2 milyon yeni olgunun katıldığı, bu olguların yaklaşık dörtte üçünün kutanöz leishmaniasis (KL) olduğu tahmin edilmektedir. Bilimsel ve medikal topluluklar tarafından 20. yüzyılda ve 21. yüzyılın başlarında leishmaniasis hakkında çok şey öğrenilmesine rağmen hastalığın kontrolü ve idaresi hala zordur. Bu makalede hastalığın en yaygın formu olan KL'nin, özellikle epidemiyolojisi ve tedavisine odaklanılmaktadır. Anahtar kelimeler: Leishmaniasis, kutanöz, epidemiyoloji, etiyopatogenez, tedavi, korunma Mehmet Harman Kutanöz Leishmaniasis Cutaneous Leishmaniasis Öz AbstractLeishmaniasis is used to describe a spectrum of diseases caused by the parasitic protozoa leishmania spp. and transmitted by infected female sandflies. There are three main forms of the disease; cutaneous, mucocutaneous, and visceral. According to the World Health Organization, almost 12 million people from 98 countries worldwide are currently infected with leishmaniasis, while 350 million people are at risk. It was reported that 2 million new cases are diagnosed every year, with three-fourth are cutaneous leishmaniasis (CL) cases. The scientific and medical communities have learnt a lot about CL during the 20 th and early 21 st centuries. However, the management and control of the disease remains a difficult task. This article was focused on the most common form of the disease, cutaneous leishmaniasis, and especially its epidemiological aspects and treatment.

show abstract

“…antimony therapy. 64 Use of liposomal amphotericin B with CL caused by L. tropica is not well-documented. Limited clinical data suggest that miltefosine may be a viable alternative for CL caused by L. tropica .…”

Section: -56mentioning

confidence: 99%

A Species-Specific Approach to the Use of Non-Antimony Treatments for Cutaneous Leishmaniasis

Ramanathan

Talaat

Fedorko

et al. 2011

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

We used a species-specific approach to treat 10 patients with cutaneous leishmaniasis diagnosed using polymerase chain reaction. Non-antimony treatments (oral miltefosine, ketoconazole, and liposomal amphotericin B) were chosen as an alternative to pentavalent antimony drugs based on likely or proven drug efficacy against the infecting species. Leishmania Viannia panamensis was diagnosed in three patients and treated successfully with oral ketoconazole. Miltefosine treatment cured two patients with L. infantum chagasi. A wide variety of Leishmania responded to liposomal amphotericin B administered for 5–7 days. Three patients with L. V. braziliensis, one patient with L. tropica, and two patients with L. infantum chagasi were treated successfully. One person with L. V. braziliensis healed slowly because of a resistant bacterial superinfection, and a second patient with L. infantum chagasi relapsed and was retreated with miltefosine. These drugs were reasonably well-tolerated. In this limited case series, alternative non-antimony–based regimens were convenient, safe, and effective.

show abstract

Leishmania tropica in northern Israel: A clinical overview of an emerging focus

Cited by 40 publications

References 23 publications

Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials

Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials

Cutaneous Leishmaniasis

A Species-Specific Approach to the Use of Non-Antimony Treatments for Cutaneous Leishmaniasis

Contact Info

Product

Resources

About